Treatment of Acinetobacter spp. infections

Infections caused by carbapenem-resistant Acinetobacter spp. are considered an urgent public health problem. Antibiotic options are scarce but new drugs may be available in the near future. We will discuss this important topic with experts in the field.
Guests:
Dr. Yohei Doi, Professor and Director, Center for Innovative Antimicrobial Therapy, University of Pittsburgh Medical Center, Pittsburgh, PA
Dr. Joseph Patrick Hornak. Fellow, Infectious Diseases, University of Texas Medical Branch, Galveston, TX
👍 Subscribe to ASM's KZbin channel at goo.gl/mOVHlK
🔬 Learn more about the American Society for Microbiology at www.asm.org
✅ Become a member today at www.asmscience.org/join
📱 Join us on social:
Facebook: / asmfan
Twitter: / asmicrobiology
Instagram: / asmicrobiology

[@jennifers7922]

Excellent discussion, thank you

[@goussharief]

3.5 years girl identified with acinetobacter in urine culture.... Plz guide

[@Lalitlait36977]

How to know whether it is pathogenic or not when isolated? If pathogenic how virulent it is?

[@karlosmiguel7963]

What is the best antibiotic to treat that in pregnant women?

[@ccbowers]

The 3g amp/sulbactam q4h is not that aggressive of a dose given that it works out to only 1g sulbactam per dose (=6g per day). The increase frequency of dosing to 4h is helpful from a PK/PD perspective if you plan on sticking to that standard dosing, but doses as high as 36g total dose per day have been studied (i.e. 12g of sulbactam per day) in small trials without reporting major adverse reactions. Most recent IDSA guidance on this topic suggests 9g IV q8h, i.e. 27g total amp/sulbactam per day (=9g sulbactam daily) for moderate to severe CRAB infections. Sounds strange when compared to typical uses of Amp/sulbactam, but the rationale makes sense when we are using the sulbactam component

[@anantmarathe362]

Frrrrfffffygffgffffgfffgfffy